Published on 10 July 2018
Implementing a treatment registry for a biosimilar: continuous safety surveillance of the biosimilar Bevax® (bevacizumab) in Argentina
Author(s): Francisco Fernández, MD, Matías Deprati, MD, Patricia Rodríguez Acedo, Eduardo Spitzer, BSc, Alvaro Romera, MD, Nadia Español, BSc
adverse drug reaction, bevacizumab, biosimilar, monoclonal antibodies, pharmacovigilance, safety profile
DOI: 10.5639/gabij.2018.0703.023
13.013 views